SB-357,134 je lek koji se koristi u naučnim istraživanjima. On deluje kao potentan, selektivan i oralno aktivan antagonist5-HT6receptora.[4] SB-357,134 i drugi 5-HT6 antagonisti manifestuju nootropne efekte u životinjskim studijama,[5][6][7] i potencijalno mogu da služe kao treatmen za kognitivne poremećaje kao što su šizofrenija i Alchajmerova bolest.
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
↑Bromidge, SM; Clarke, SE; Gager, T; Griffith, K; Jeffrey, P; Jennings, AJ; Joiner, GF; King, FD i dr.. (2001). „Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134)”. Bioorganic & Medicinal Chemistry Letters11 (1): 55–8. DOI:10.1016/S0960-894X(00)00597-7. PMID11140733.